Objective. To review the literature on usage of the levonorgestrel intrauterine system (LNG IUS) An observational study and isolated reports of women with adenomyosis report significant symptomatic relief in these women.
Introduction
The levonorgestrel intrauterine system (LNG IUS: Mirena ® , Schering, UK) is a highly effective contraceptive 1 and is extremely helpful in treating menorrhagia 2 among other confirmed or highly suggestive non-contraceptive benefits. 3 Randomised trials have confirmed its superior efficacy when compared with conventional medical treatment for menorrhagia 4 and its comparability with hysteroscopic surgical ablation of the endometrium. 5 Its advantages over endometrial ablation are: relative simplicity as well as reversibility, contraceptive effect 6 and the relief of pelvic pain. 7 The latter is frequently of even greater importance to the woman herself and is seldom relieved by, for example, transcervical resection of the endometrium (TCRE). 8 Recently published studies suggest the potential of the IUS to reduce hysterectomy waiting lists, 9, 10 and it is generally accepted as a first option in women with heavy periods who also require contraception.
Available information on the LNG IUS as a treatment for menorrhagia is mainly derived from studies of carefully selected women with dysfunctional uterine bleeding in research settings. However, in routine clinical practice, heavy menstrual loss is often due to underlying uterine pathology, most commonly fibroids and adenomyosis. It is therefore important to consider the possible effect of these conditions on the efficacy of the device and with this in mind, the available literature was reviewed.
Effect of uterine fibroids
Uterine myomas (fibroids) are benign tumours, which primarily contain smooth muscle, but may have varying densities of fibrous elements. Postmortem studies suggest that up to 50% of all women have fibroids 11 and that these are commonly associated with heavy menstrual loss. 12 This means practitioners who use the LNG IUS will undoubtedly encounter fibroids on a regular basis. Significant enlargement or distortion of uterine cavities, as well as excessive bleeding secondary to fibroids, can potentially affect the positioning of the device and hence efficacy.
In addressing this issue, one also has to consider the possible effect of the released progestogen (levonorgestrel) on existing fibroids. This is a controversial subject as in vitro 13 and some clinical studies 14 have suggested a stimulatory effect in certain circumstances of some progestogens on uterine fibroids. Long-term contraceptive studies, however, have demonstrated protection from the complications of fibroids in association with use of depotmedroxyprogesterone acetate (DMPA) 15 and the LNG IUS 7 . Intramuscular DMPA causes moderately high systemic levels of the progestogen medroxyprogesterone and results in ovarian and endometrial suppression. In marked contrast, the LNG IUS causes selective endometrial suppression due to high endometrial and very low systemic concentration of the progestogen levonorgestrel, with very little effect on ovarian function. 16 The apparent protective effect of these two forms of contraception, despite different Ikomi et al systemic levels of progestogen, has led some to hypothesise that the main mechanism of this protection may be their common effect of endometrial suppression. 17 This hypothesis is supported by the fact that some endometrial growth factors have been shown to be mitogenic for myoma cells in culture. 18 Although encouraging, this protective effect cannot simply be extrapolated to women with existing symptomatic fibroids, and separate studies are needed.
A pilot study of five menorrhagic LNG IUS users with fibroids showed a reduction in uterine volume after 6-18 months of use 19 and a similar effect is documented in isolated reports. 20 One retrospective study did not demonstrate an adverse effect on overall success rates due to fibroids. 21 However, a less reassuring finding in this study was the fact that all expulsions of the device were associated with the presence of uterine fibroids and the factors that significantly contributed to this association were major uterine enlargement (volume > 148 ml) and pretreatment anaemia. The deductions were that uterine enlargement can affect positioning of the device and anaemia is indicative of truly excessive blood loss, which is more likely to dislodge the device. This study also reported that in the majority of women who required hysterectomy following failure with the LNG IUS, histological examination of the uterine specimen confirmed the presence of fibroids. Reports of prolapsed pedunculated fibroids following insertion of the LNG IUS 22 lend further support to a recommendation for extra vigilance when dealing with fibroid uteri.
Although some of the available evidence does raise concern, published studies on LNG IUS usage in menorrhagic women do include some women with fibroids, and successful outcomes have been reported. Therefore, it would be simplistic to try and base any recommendations for selection only on the presence or absence of fibroids, as this will simply deny many potential beneficiaries. Nevertheless, the fact remains that no one has specifically addressed, in well-designed prospective trials, the issue of how their presence affects the efficacy of the device. Thus there is a lack of clear guidelines about LNG IUS usage in women with fibroid uteri. If prospective studies do confirm an adverse relationship, other important considerations are whether there is a critical uterine size and whether alternative approaches, such as initial adjunctive treatment with other suppressive agents such as GNRH analogues, make a difference. The reasoning behind this assertion is the fact that expulsion of the LNG IUS (like all intra-uterine devices) is most common during heavy menstrual loss, particularly the first and second such heavy loss after insertion. It has been reported that 40% of women with objective menstrual loss in excess of 200 ml have uterine fibroids, whereas only 10% of those with a loss of 80-100 ml are affected. 23 In view of the association between fibroids and heavy menstrual flow, it might well be beneficial to abolish the first one or two menses during early use of the LNG IUS in women with fibroids.
Effect of adenomyosis
The existence of endometrial tissue within the myometrium leads to heavy and usually painful menstrual loss. Diagnosis has traditionally relied on clinical findings with histological confirmation following hysterectomy, as conventional medical treatment tends to be unhelpful. Major developments include an ability to detect this condition using MRI scans, and studies have confirmed the LNG IUS to be an efficacious method of treating the symptoms of this condition. 24 In this prospective study the use of LNG IUS in patients with adenomyosis associated menorrhagia led to symptomatic relief in 92% of the patients after 1 year follow-up. Significant increases in serum haemoglobin and ferritin were also observed.
A more recent case report described a significant reduction in of a very large adenomyotic uterus associated with use of the LNG IUS. 25 This suggests a potential role in the treatment of adenomyosis irrespective of uterine size, but further studies are needed.
Conclusions
Practitioners increasingly see the LNG IUS as a panacea to the problem of excessive menstrual loss, and in Western European countries outside Scandinavia, formal licenses for treating heavy periods are anticipated. In the continuing absence of relevant prospective studies of women with pathology-related menorrhagia, and based on the currently available evidence, one concludes by suggesting a cautious approach.
When fibroids or adenomyosis are suspected, routine initial ultrasound scan of the uterus should be combined with sonohysterography or hysteroscopy to check the contours of the uterine cavity. Cavity distortion precludes insertion of the device. Significant uterine enlargement or documented anaemia may increase the risk of expulsion, and under these circumstances there may be scope for initial adjunctive treatment as well as suitable counselling of the woman.
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